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ABSTRACT 
Hepatitis C is major cause of chronic liver disease. It has been recognised as a global health problem because of the progression to cirrhosis and 
hepatocellular cancer. Quantization and genotyping of HCV RNAs are important to determine the optimal duration of anti-viral therapy and 
predict likelihood of response. Total 77 samples were tested biochemically, serologically and molecular assay (Roche COBAS TaqMan 48 Real 
Time PCR). Out of 77 cases 33(42.85%) were with high viral load (>103IU/ ml of HCV RNA) and low viral load (below 103IU/ml) 2 (2.59%) and 
42 (54.54%) were target not detected (below 25 IU/ml). Genotype 3 was prevailed with 68.42% out of 35 cases followed by HCV genotype 
15.78% in 1, 5.26% in 2 and 6, 2.63% in 1b and 4. In addition, our studies showed that genotype 1, 2, 4 and 6 (mixed genotype was detected in 1 
cases with viral load 6.62 × 108IU/ml). Total protein content in serum in all the cases was average except 04 cases that was having low protein 
content. 02 cases were having low uric acid content that was having high viral load. From all high positive (high viral load)  cases which were 
further diagnosed for their genotyping in which genotype 3 was prevalent following by genotype1, 1b, 2, 4 and  6. Study signifies the gene based 
diagnosis and its clinical relevance for the proper management of the patients.  
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INTRODUCTION  
According to the Centre for Disease Control and Prevention 
(CDC, 2009), hepatitis C is defined as a contagious liver 
disease resulting from infection with the hepatitis C virus 
(HCV) [1]. HCV is the main etiological agent for chronic 
hepatitis, liver cirrhosis and hepatocellular carcinoma. HCV 
is an enveloped, positive sense, single-stranded; RNA virus 
with a diameter of about 50 nm, its genome is of about 9.5 
kb. It is classified as a separate genus (Hepacivirus) within 
the Flaviviridae family [2-4]. Like a blood-borne virus, HCV 
can be transmitted by blood and blood products. There are 
three forms of viruses present in the serum of infected 
individuals, including free virions, virions associated with 
immuneglobulins and virions associated with very low 
density and low density lipoproteins. There are very few 
studies on the clinical correlation of the HCV RNA viral load 
and its implications on other affected body organs, as well as 
on the impact of different HCV genotypes for the proper 
management of patients in the northern regions of India [5-
12]. This study is focus on Hepatitis C Virus and its Genetic 
Diversity in clinical Isolates from Uttarakhand population 
MATERIALS AND METHODS  
Total number of cases with serologically HCV reacted were 
considered for the proposed study. The whole blood sample 
collected in lavender coloured vacutainer tube which ensure 
mixing anticoagulant (EDTA) with blood to prevent clotting 
and samples is transported in properly sealed insulted 
thermocol box with ice gel pack maintaining 4°C 
temperature[13,14]. Central Molecular Research Laboratory 
day to day and the same day serum was separated for further 
processing. The cases in which we have targeted the 
Untranslated region (UTR) for HCV RNA viral load 
monitoring  from the symptomatic patients and RNA was 
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isolated by Roche high pure system (cat P/N: 03 531 376-
001) solid phase nucleic acid extraction method. 
RESULT 
Viral load for HCV was done by Roche COBAS TaqMan 48 RT 
PCR with detection limit 25IU/ml-1.10×108IU/ml in which 
HCV RNA viral load was detected for all the 77 cases it was 
found that out of 77 cases were high viral load (>103IU/ ml 
of HCV RNA) 33(42.85%) and low viral load (below 
103IU/ml) 2(2.59%) and TND (below 25 IU/ml) 42 
(54.54%).The cases with high viral load were further 
subjected to HCV genotyping by Real time PCR in which we 
have targeted type and subtypes of the HCV gene Conserved 
regions of different HCV genotypes including 1b, 1, 2, 3, 4, 5, 
6 as well as TaqMan florescence probes to achieved 
genotyping detection  of HCV RNA though fluorescent signal 
changes. Further all the case with HCV RNA viral load ≥ 103 
IU/ml were further compared for HCV genotyping. It was 
observed that out of 77 cases, 35 were HCV RNA viral load ≥ 
103, which was further considered for HCV genotyping. 
Genotyping was done by Sansure Biotech Inc. (cat number 
655654654) The HCV genotyping was done as per 
manufacturer protocol which detects HCV genotype 1, 1b, 2, 
3, 4, 5, 6 gene target was Conserved region by  Qiagen RT PCR 
open channel. Genotype 3 was prevailed with 68.42% out of 
35 cases followed by HCV genotype 15.78% in 1, 5.26% in 2 
and 6, 2.63% in 1b and 4.Also our studies showed that 
genotype 1, 2, 4 and 6 (mixed genotype was detected in 1 
cases with viral load 6.62 × 108 IU/ml). 
Further, Biochemical profiling was done by the cases. 
Biochemical examination (bilirubin, SGOT, SGPT, albumin, 
alkaline phosphatase, TSH etc.). Total bilirubin was in 
normal range of 0.2-1.3mg/dl among all the cases except 4 
cases which was having high bilirubin. Gamma glutamyl 
transferase (GGT) was depicted low in 3 cases and high in 12 
cases from normal range of 12-43 U/L. The total protein was 
average in all the cases between the ranges of 6.30-8.20g/dl 
whereas 7 cases were below this range of total protein. The 3 
cases was having low uric acid content whereas rest of the 
cases was in normal range of 3.5-8.5mg/dl. The 11 cases was 
having low and 3 cases was high Creatinine serum content 
whereas rest of the cases was in normal range of 0.8-
1.5mg/dl. 
 
Table 1: Gender wise Distribution of high and low viral load 
 Female Male 
HCV RNA viral load status 43 (55.84%) 34(44.15%) 
TND (Target not detected )below 25 IU/ml 25 (59.52%) 17(40.47%) 
High viral load (above103 IU/ml) 18 (54.54%) 15 (45.45%) 
Low viral load(below 103 IU/ml) 2(100%) 0 (0%) 
 
 
Figure 1: Gender wise Distribution of high and low viral load for Hepatitis C Virus 
 
Figure 2: Pie chart of Positive and Negative cases of Hepatitis C Virus 
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Table 2: Age wise Distribution of Hepatitis C Cases 
Age 
(years) 
Total Number of cases 
High viral 
load(>103IU/ml) 
Target not detected 
(Below 25IU/ml) 
Low viral load 
(below 103) 
0-20 0 - - - 
21-40 28 13(46.42%) 16(57.14%) 2 
41-60 38 16(42.10%) 20(52.63%) - 
Above60 11 4(36.36) 6(54.54%) - 
 
Table 3: Genotype distribution of HCV Cases 
HCV Genotype Total cases 
1 6(15.78%) 
1b 1(2.63%) 
2 2(5.26%) 
3 26(68.42%) 
4 1(2.63%) 
5 - 
6 2(5.26%) 
7 - 
 
 
Figure 3: Genotypic prevalence among suspected cases of HCV 
 
Figure 4: Multiple Genotype in Hepatitis C Virus 
Table 4: Spectrum of HCV viral load 
Range of HCV 
RNA titer 
(IU/ml) 
No. 
of 
cases 
Total no. of Cases 
with HCV RNA 
viral≥500 IU/ml 
HCV 
Genotypes 
detected 
 
HCV Genotype/s distribution 
1 1b 2 3 4 5 6 
TND 42 None None None None None None None None None 
1.10×101 
1.10×103 
2 No No No No No No No No No 
1.00×104 
1.00×107 
19 19 1, 2, 3, 4, 6 
 
 
3 
 
No 
 
2 
 
15 
 
1 
 
- 
 
2 
>1.00×108 14 14 1b,1,3 3 1 - 14 - - - 
Total 77 33  06 
(15.78%) 
01 
(2.63%) 
02 
(5.26) 
29 
(68.42) 
01 
(2.63%) 
- 02 
(5.26) 
0.00%
100.00%
percentage 
percentage
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Table 5:  Comparative result interpretation for biochemical investigations LFT 
 
Total 
number of 
Cases 
Range of 
1SGOT  
(14 - 36) U/L 
Range of 
2SGPT (9- 12) 
U/L 
Range of 3AP (38- 
126 ) U/L 
Range of Bilirubin 
(0.2-1.3) mg/dl 
Range of Globulin 
(2.3-3.5) g/dl 
Cases greater 
than upper 
value of 
normal range 
77 15 (19.48%) 12 (15.58%) 7 (9.09%) 4 (5.19%) 7 (9.09%) 
Total Cases 
lower than 
lower value 
of normal 
range 
77 2 (2.59%) 1 (1.29%) 1(1.29%) 1(1.29%) 00 
Total Cases 
within 
normal range 
77 20 (25.97%) 24 (31.16%) 28 (36.36%) 32 (41.55%) 29 (37.66%) 
1SGOT = Serum glutamic oxaloacetic transaminase 
2SGPT = Serum glutamic pyruvic transaminase 
3AP = Alkaline phosphatase 
Table 6:  Comparative result interpretation for biochemical investigations RFT 
Cases greater than 
upper value of 
normal range 
77 3 (3.89%) 3 (3.89%) 00 (0%) 00 (0) % 2 (2.59%) 
Total Cases lower 
than lower value of 
normal range 
77 00 (0%) 11 (14.28%) 4 (5.19%) 6 (7.79%) 00 (0%) 
Total cases within 
normal range 
77 16 (20.77%) 9 (11.68%) 11 (14.28%) 9 (11.68%) 13 (16.88%) 
 
DISCUSSION 
In this study, we have taken a total no. of 77 symptomatic 
specimens for HCV tri dot examination. Only 1(1.29%) case 
was non-reactive for tri dot out of 77 cases. The sensitivity 
considered for HCV tri dot in this study approximately 95%-
99%. However, there are conflicting reports on the 
relationship between the biochemical markers of 
inflammation alanine transaminase (ALT), histological 
degree of inflammation, and serum HCV-RNA levels by 
reverse transcription (RT)-PCR. In individuals with chronic 
hepatitis C, viral load and elevated serum ALT levels may 
have clinical relevance. ALT is most concentrated in liver 
and released into the bloodstream as the result of liver 
injury[15,16,17]. It, therefore, serves as a fairly specific 
indicator of liver status. SGOT is normally found in a 
diversity of tissues including liver, heart, muscle, kidney, and 
brain. It is released into serum when any one of these tissues 
is damaged. It is, therefore, not a highly specific indicator of 
liver injury. The present study revealed that SGOT levels 
varied significantly among the three groups of HCV 
genotypes. All other biochemical parameters were deranged 
but changes remained non-significant as also reported 
earlier. A low globulin level in patients with hepatitis C can 
be a sign of cirrhosis (advanced liver disease). Globulin 
levels can go up and down slightly. Very low globulin levels 
can cause symptoms of edema, or fluid accumulation, in the 
abdomen (called ascites) or in the leg. Low levels of total 
protein in the blood can occur because of impaired function 
of the liver. A high alkaline phosphatase level does not 
reflect liver damage or inflammation. A high alkaline 
phosphatase level occurs when there is a blockage of flow in 
the biliary tract or a build-up of pressure in the liver often 
caused by a gallstone or scarring in the bile ducts. The level 
of SGOT, SGPT, Alkaline phosphatase, Bilirubin and Globulin 
are found maximum in high HCV RNA viral load cases in 
comparison to target not detected in the current study. The 
high viral load cases must be further processed for 
genotyping. Knowing the viral load before starting treatment 
is useful because patients with “high” viral load scan have a 
difficult time getting the virus to become completely 
undetectable on treatment [18,19,20]. Target was not 
detected are the cases were the hepatitis C virus is present 
in the bloodstream, but at a very low level, too low to be 
measured by a quantitative test. Unlike the flu virus, which 
has an incubation period of less than a week, incubation for 
chronic HCV can take between 14 to 180 days. The 
incubation for acute hepatitis C is typically about six to 10 
weeks. The incubation period of HCV differs from that of 
other types of hepatitis. Viral infection may also be 
depending on the age of an individual and its immunity. 
Cases with 41-60 years of age group in the present study 
were mostly affected with HCV infection, having maximum 
number of HCV RNA high viral load with 16 (48.18%), 
20(52.63%), TND and 2(5.01) cases. This might be due to 
repeatedly being exposed to infected blood. The age group of 
0-20 no viral load was detected in this age group. This may 
be due to protective antibody titer against HCV due to 
vaccination in early age. Accretion of nucleotide switch in 
the HCV genome results in diversiﬁcation and evolution into 
different genotypes. Differences among HCV genotypes in 
geographic distributions have provided investigators with 
epidemiologic markers that can be used to find the source of 
HCV infection in a given population & for further 
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prognosis[21]. This assay enabled us to detect 6HCV 
genotype (1, 1b, 2, 3, 4, 5, 6). However, HCV genotype 3 was 
most frequently detected. HCV genotype 3 is also the most 
common genotype in India and Pakistan. HCV genotype 3 
contributes to the development of steatosis (fatty liver 
disease) and insulin resistance, both of which can directly 
influence HCV disease progression including cirrhosis and 
liver cancer. This may also contribute to the risk of liver 
failure. There is evidence to suggest that people with this 
genotype experience a faster rate of fibrosis progression. 
Our study were also with maximum number of cases with 
HCV RNA viral load >500 IU/ml with HCV genotype 3, which 
was found  68.42% in patients and other genotypes and 
subtypes were 1 (15.78%), 1b (2.63%), 2 (5.26%), 4(2.63%), 
6 (5.26%) respectively.  Thus, the genomic composition of 
the HCV and its difference in genetic expression can play an 
important role for the management of the patients affected 
by this lethal virus. Study revealed that the prevalence of 
genotype 1 in HCC patients was significantly higher than in 
chronic hepatitis and liver cirrhosis patients. Multiple 
logistic regression analysis revealed that, after adjusting for 
age and serum HCV RNA levels, HCV genotype 1 and 1b 
infection was still a significant risk factor. From the above 
result discussed, it is evident that for positive cases in which 
viral load detected was very high (> 1.10 X 108) in 14 cases 
whereas in only 1 case was found very low viral load <25IU/ 
ml. Total prevalence of HCV viral load was calculated was 
45.45% of total suspected cases. In some positive cases like 
case no.19 levels of bilirubin, and globulin were found to be 
high among all the cases whereas Gamma glutamyl 
transferase(GGT) was depicted low in 5 cases and high in 8 
cases. Total protein content in serum in all the cases was 
average except 4cases which was having low protein 
content.2 cases was having low uric acid content which was 
having high viral load. From all high positive(high viral load) 
cases which were further diagnosed for their genotyping in 
which genotype 3 was prevalent following by genotype1, 1b, 
2, 4 and  genotype 6. 
CONCLUSION 
Trace amount of HCV RNA from successfully treated patients 
can be infectious. We do not know the long term efficacy of 
treatment with the new generation of DAAs, particularly 
with interferon free regimens; and generation of potential 
resistant virus. Recent advances in our understanding of 
HCV structure, genome and its lifecycle have revealed 
numerous target sites for potential pharmacological 
invention. These should help in further improving HCV 
treatment. Efforts by investigators across the globe have led 
to detailed molecular characterization of the virus but 
despite these advancements in our standing, many 
fundamental questions will remain unanswered. The 
membrane associated RNA replication complex presumably 
involves various host proteins. However, the precise host 
components and mechanisms for replication are not 
understood yet. 
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